Previous 10 | Next 10 |
Focused on Novel Combination of Clinical-Grade Exosomes and Hydropeptides for Cosmeceutical and Orthopedic Product Development Signed Three-Way Material Transfer Agreement between Avalon GloboCare, HydroPeptide and Weill Cornell Medicine FREEHOLD, N.J., April 28, 2020 (GLOBE...
Avalon GloboCare (NASDAQ: AVCO ) +44% on advancing immunotherapeutic program towards combatting cytokine storm associated with COVID-19 lung damage and mortality. More news on: Avalon GloboCare Corp., Eros International Plc, VBI Vaccines Inc., Stocks on the move, , Read more ....
Completed Functional Studies of Six QTY Code Designed Variant Cytokine Receptors as “Molecular Mop” to Remove Excessive Cytokines (“Cytokine Storm”) Related to Coronavirus Infection and Cellular Immunotherapy Jointly Filed Provisional Patents with Professor ...
The S&P 500 gained 8.82% last week as a consequence of growing optimism about a restart of the economy very soon as the number of new Covid-19 cases is slowing down. After recommending to increase cash positions at the end of 2019, I do believe that it is interesting to cautiously put so...
FREEHOLD, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it will present at the 32 nd Annual ROTH Conference being held on March 15-17, 2020 at The Ritz-Carlt...
FREEHOLD, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that its President and Chief Executive Officer, David Jin, M.D., Ph.D., will co-chair a session, entitled &...
FREEHOLD, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today announced its Chief Executive Officer, Dr. David Jin, will present at the Biotech Showcase™ 2020 conference be...
Forms Major Regional Hub in China for CellTech Industry Partnership Delivers Synergy of Infrastructural Resources for Clinical Development and Bioprocessing Technologies in Cellular Therapy FREEHOLD, N.J., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clini...
FREEHOLD, NJ / ACCESSWIRE / November 20, 2019 / Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of cell-based technologies and therapeutics, today announced that management will present at the 12th Annual LD Micro Main Event institutional investor conference being held on De...
Every decade or so, dark clouds will fill the economic skies, and they will briefly rain gold. When downpours of that sort occur, it’s imperative that we rush outdoors carrying washtubs, not teaspoons. And that we will do. - Warren Buffett Concerns relating to the China Trade Wa...
News, Short Squeeze, Breakout and More Instantly...
Avalon GloboCare Corp. Company Name:
AVCO Stock Symbol:
NASDAQ Market:
Company to Begin Trading under New Symbol “ALBT” on November 10, 2022 Symbol Change Better Reflects Avalon’s New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon...
Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a ...
Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ: AVCO) , a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Ch...